Nurix Therapeutics (NRIX) – Research Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Nurix Therapeutics (NASDAQ: NRIX) in the last few weeks:

• 7/28/2026 – Nurix Therapeutics had its price target raised by Morgan Stanley from $36.00 to $38.00. They now have an “overweight” rating on the stock.
• 7/22/2026 – Nurix Therapeutics had its price target raised by UBS Group AG from $23.00 to $31.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Nurix Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/13/2026 – Nurix Therapeutics had its price target raised by Mizuho from $30.00 to $34.00. They now have an “outperform” rating on the stock.
• 7/12/2026 – Nurix Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 7/10/2026 – Nurix Therapeutics had its price target raised by Truist Financial Corporation from $32.00 to $34.00. They now have a “buy” rating on the stock.
• 7/10/2026 – Nurix Therapeutics had its price target raised by HC Wainwright from $32.00 to $34.00. They now have a “buy” rating on the stock.
• 7/10/2026 – Nurix Therapeutics had its price target raised by Stifel Nicolaus from $34.00 to $40.00. They now have a “buy” rating on the stock.
• 7/10/2026 – Nurix Therapeutics had its price target raised by Royal Bank Of Canada from $30.00 to $33.00. They now have an “outperform” rating on the stock.
• 7/10/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $34.00 price target on the stock.
• 7/10/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $32.00 price target on the stock.
• 6/29/2026 – Nurix Therapeutics is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $28.00 price target on the stock.
• 6/18/2026 – Nurix Therapeutics had its price target raised by Robert W. Baird from $26.00 to $33.00. They now have an “outperform” rating on the stock.
• 6/15/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $34.00 price target on the stock.
• 6/10/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.
• 6/9/2026 – Nurix Therapeutics had its price target raised by BTIG Research from $30.00 to $32.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Nurix Therapeutics had its price target raised by Truist Financial Corporation from $30.00 to $32.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Nurix Therapeutics was downgraded by Wells Fargo & Company from “overweight” to “hold”. They now have a $25.00 price target on the stock, down from $28.00.
• 6/8/2026 – Nurix Therapeutics had its price target raised by Jefferies Financial Group Inc. from $41.00 to $45.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Nurix Therapeutics had its price target raised by Needham & Company LLC from $26.00 to $34.00. They now have a “buy” rating on the stock.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 5,394 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $20.00, for a total value of $107,880.00. Following the completion of the sale, the insider directly owned 115,005 shares in the company, valued at approximately $2,300,100. This represents a 4.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 14,055 shares of the company’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $16.60, for a total value of $233,313.00. Following the completion of the sale, the chief financial officer owned 37,592 shares of the company’s stock, valued at $624,027.20. This represents a 27.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.70% of the stock is owned by corporate insiders.

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.